About cns pharmaceuticals inc - CNSP
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.
CNSP At a Glance
CNS Pharmaceuticals, Inc.
2100 West Loop South
Houston, Texas 77027
| Phone | 1-800-946-9185 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -15,850,564.00 | |
| Sector | Health Technology | Employees | 8 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CNSP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.734 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.284 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.072 |
CNSP Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,981,320.50 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CNSP Liquidity
| Current Ratio | 1.965 |
| Quick Ratio | 1.965 |
| Cash Ratio | 1.756 |
CNSP Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -182.985 |
| Return on Equity | -296.295 |
| Return on Total Capital | -326.74 |
| Return on Invested Capital | -296.295 |
CNSP Capital Structure
| Total Debt to Total Equity | 7.265 |
| Total Debt to Total Capital | 6.773 |
| Total Debt to Total Assets | 3.81 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |